Contamination by human and veterinary pharmaceutical derivatives refers to the undesirable presence of drug residues in the environment, including water, soil, and living organisms. This contamination can occur at various stages, including production, consumption, and disposal of medications. Main sources include releases from pharmaceutical facilities, wastewater discharges containing drug residues, and uncontrolled use of veterinary drugs in agriculture.
Pharmaceutical contamination raises environmental and health concerns, impacting ecosystems and posing risks of antibiotic-resistant bacteria emergence. Conventional wastewater treatment methods may not efficiently remove these compounds, contributing to their persistence. Efforts are underway to develop advanced treatment technologies and sustainable pharmaceutical waste management practices. Regulations aim to limit releases and promote environmental monitoring to assess the extent of contamination by pharmaceutical derivatives.

Pharmaceuticals

Contamination by human and veterinary pharmaceutical derivatives refers to the undesirable presence of drug residues in the environment, including water, soil, and living organisms. This contamination can occur at various stages, including production, consumption, and disposal of medications. Main sources include releases from pharmaceutical facilities, wastewater discharges containing drug residues, and uncontrolled use of veterinary drugs in agriculture. Pharmaceutical contamination raises environmental and health concerns, impacting ecosystems and posing risks of antibiotic-resistant bacteria emergence. Conventional wastewater treatment methods may not efficiently remove these compounds, contributing to their persistence. Efforts are underway to develop advanced treatment technologies and sustainable pharmaceutical waste management practices. Regulations aim to limit releases and promote environmental monitoring to assess the extent of contamination by pharmaceutical derivatives.

IMMUNOGLOBULIN (ANTI-A, ANTI-B ANTIBODIES TEST POSITIVE CONT

IMMUNOGLOBULIN (ANTI-A, ANTI-B ANTIBODIES TEST POSITIVE CONT

NA

DISCOVER
IMMUNOGLOBULIN (ANTI-A, ANTI-B ANTIBODIES TEST NEGATIVE CONT

IMMUNOGLOBULIN (ANTI-A, ANTI-B ANTIBODIES TEST NEGATIVE CONT

NA

DISCOVER
TIMOLOL IMPURITY F CRS (15 MG)

TIMOLOL IMPURITY F CRS (15 MG)

30165-96-9

DISCOVER
IMATINIB MESILATE CRS (120 MG)

IMATINIB MESILATE CRS (120 MG)

220127-57-1

DISCOVER
IMATINIB FOR SYSTEM SUITABILITY CRS (5 MG)

IMATINIB FOR SYSTEM SUITABILITY CRS (5 MG)

220127-57-1

DISCOVER
IMATINIB IMPURITY F CRS (15 MG)

IMATINIB IMPURITY F CRS (15 MG)

NA

DISCOVER
IMATINIB IMPURITY H CRS (130 MG)

IMATINIB IMPURITY H CRS (130 MG)

350-03-8

DISCOVER
IMATINIB IMPURITY A CRS (0.03MG)

IMATINIB IMPURITY A CRS (0.03MG)

NA

DISCOVER
TOLTERODINE TARTRATE CRS (5 MG)

TOLTERODINE TARTRATE CRS (5 MG)

124937-52-6

DISCOVER
TOLTERODINE FOR SYSTEM SUITABILITY CRS (5 MG)

TOLTERODINE FOR SYSTEM SUITABILITY CRS (5 MG)

NA

DISCOVER
TIZANIDINE IMPURITY B CRS (10MG)

TIZANIDINE IMPURITY B CRS (10MG)

64461-82-1

DISCOVER
TOLTERODINE IMPURITY E CRS (15 MG)

TOLTERODINE IMPURITY E CRS (15 MG)

NA

DISCOVER